Ipolipid (Gemfibrozil)

Gemfibrozil acts on lipid metabolism to lower triglyceride concentrations in the blood.

• Hypertriglyceridemia: reduces serum triglyceride levels, aiding in the management of severe elevations and lowering the risk of pancreatitis.
• Mixed hyperlipidemia: lowers triglycerides while modestly increasing HDL‑C, contributing to an improved overall lipid profile in patients with combined cholesterol abnormalities.
• Prevention of pancreatitis secondary to severe hypertriglyceridemia: helps control extremely high triglyceride concentrations, thereby decreasing the likelihood of acute pancreatitis episodes.

• Gemfibrozil activates peroxisome proliferator‑activated receptor‑α (PPARα), which increases the synthesis of lipoprotein lipase and reduces hepatic production of very‑low‑density lipoprotein (VLDL). The enhanced lipoprotein lipase activity accelerates the catabolism of triglyceride‑rich lipoproteins, while decreased VLDL synthesis limits the release of triglycerides into circulation, resulting in lower plasma triglyceride levels and a modest rise in high‑density lipoprotein cholesterol.

Gemfibrozil may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia.
• Headache: mild to moderate intensity.
• Elevated liver enzymes: transient increases in ALT or AST.
• Muscle pain: mild myalgia without weakness.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown that can lead to renal failure.
• Severe hepatotoxicity: marked elevation of liver enzymes or jaundice.
• Gallstones: formation of cholesterol gallstones in predisposed individuals.
• Blood dyscrasias: rare cases of leukopenia or thrombocytopenia.

When prescribing Gemfibrozil, clinicians should observe several safety considerations.

• Liver function monitoring: assess hepatic enzymes before treatment and periodically during therapy.
• Renal impairment: adjust use in patients with severe kidney disease and monitor renal function.
• Muscle toxicity: avoid concomitant use with statins and counsel patients to report unexplained muscle pain or weakness.
• Pregnancy contraindication: do not use in pregnancy due to known fetal risk (Category X).
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Gemfibrozil interacts with several medicines, requiring careful management to avoid adverse outcomes.

Major Interactions (Avoid)

• Statins (especially simvastatin, lovastatin): increased risk of rhabdomyolysis; avoid co‑administration.
• Anticoagulants (warfarin): potentiates anticoagulant effect, may require dose adjustment and INR monitoring.

Moderate Interactions (Monitor Closely)

• Oral hypoglycemics (e.g., sulfonylureas): may enhance hypoglycemic effect; monitor blood glucose.
• Cyclosporine: increased cyclosporine levels; monitor renal function and drug concentrations.
• Bile acid sequestrants (e.g., cholestyramine): may reduce gemfibrozil absorption; separate dosing times.